---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-010318"
form_type: "8-K"
ticker: "PYXS"
cik: "0001782223"
company_name: "Pyxis Oncology, Inc."
filed_at: "2023-03-28T23:59:59+00:00"
generated_at: "2026-06-17T13:13:16.405416+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "high"
source: SEC EDGAR
---

# Pyxis Oncology reprices executive stock options to $2.21 per share

## Summary
- Board approved reducing exercise prices of outstanding pre-IPO options from $5.34-$8.71 to $2.21, the closing price on March 24, 2023.
- CEO Lara Sullivan had 1,052,286 options repriced; CFO/COO Pamela Connealy 332,569; CMO Jay Feingold 174,774.
- Repricing applies only to options granted under the 2019 Plan to current employees; all other terms unchanged.
- Board cites improved retention and motivation without additional equity dilution or cash compensation.

## SEC filing metadata
- accession: 0000950170-23-010318
- form_type: 8-K
- ticker: PYXS
- cik: 0001782223
- company_name: Pyxis Oncology, Inc.
- filed_at: 2023-03-28T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1782223/000095017023010318/0000950170-23-010318-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1782223/000095017023010318/pyxs-20230328.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-010318
- JSON: https://secwatch.observer/filing/0000950170-23-010318.json
- Plain text: https://secwatch.observer/filing/0000950170-23-010318.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.